GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Vigil Neuroscience
Vigil Neuroscience is a biotech company specializing in the treatment of rare neurological diseases. Its stock price is driven by news of clinical trials. The chart reflects the binary risks and hopes associated with the development of new drugs.
Share prices of companies in the market segment - Neuro
Vigil Neuroscience is a biopharmaceutical company focused on developing treatments for rare neurodegenerative diseases by targeting microglia. We've categorized it under "Neurology." The chart below shows how the market is evaluating new approaches to treating brain diseases.
Broad Market Index - GURU.Markets
Vigil Neuroscience is a biotech company specializing in developing drugs to treat rare neurodegenerative diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Vigil shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VIGL - Daily change in the company's share price Vigil Neuroscience
Vigil Neuroscience, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for the treatment of neurodegenerative diseases.
Daily change in the price of a set of shares in a market segment - Neuro
Vigil Neuroscience is a biopharmaceutical company specializing in microglia-targeted drugs for the treatment of rare neurodegenerative diseases. Neuroscience is a risky field. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Vigil Neuroscience is a biotech company working on treating neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Vigil Neuroscience
Vigil Neuroscience's year-over-year performance is a story about its drug development for rare neurodegenerative diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its microglia-targeted antibodies could offer a new approach to treating these severe conditions.
Annual dynamics of market capitalization of the market segment - Neuro
Vigil, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vigil Neuroscience is a biotech company focused on rare brain diseases. Its stock price is completely uncorrelated with the market, but is a direct response to clinical trial data. Its earnings chart is a heartbeat of patient and investor hopes.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Vigil Neuroscience
Vigil is a biotech company focused on neurodegenerative diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of its drug trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Neuro
Vigil Neuroscience is a biotech company focused on developing drugs to treat rare neurodegenerative diseases by targeting microglia, the brain's immune cells. The graph below illustrates the dynamics of the biotech sector, where understanding the role of microglia opens new treatment approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vigil Neuroscience is a biotech company developing drugs to treat rare neurodegenerative diseases. Its stock lives in the world of clinical trials. The success or failure of a single study can dramatically change the company's value, ignoring the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Vigil Neuroscience
Vigil Neuroscience, a biotech focused on rare neurodegenerative diseases, is experiencing high volatility. Weekly stock performance is driven by news of clinical trials, reflecting the high risks and hopes of finding cures for brain diseases.
Weekly dynamics of market capitalization of the market segment - Neuro
Vigil Neuroscience and the entire neuroscience biotech sector are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vigil Neuroscience is a biotech company focused on neuroscience. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that VIGL's performance is almost uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
VIGL - Market capitalization of the company Vigil Neuroscience
Vigil Neuroscience's chart is a financial map of the fight against rare brain diseases. The market cap of this company, focused on the role of microglia in neurodegeneration, reflects the hopes for its innovative approach. Its dynamics are a barometer of progress in clinical trials and the belief that its drugs can help patients with severe neurological disorders.
VIGL - Share of the company's market capitalization Vigil Neuroscience within the market segment - Neuro
Vigil Neuroscience specializes in rare neurodegenerative diseases. The company's market share in the biotech sector reflects its potential to develop drugs for poorly understood diseases. Its low market share is typical for a company in the research stage, but it could skyrocket if successful.
Market capitalization of the market segment - Neuro
Vigil Neuroscience is a biotech company focused on rare neurodegenerative diseases. The chart below shows the overall market capitalization of this complex sector. Its dynamics are a barometer of investor hopes that science will find the keys to curing brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vigil Neuroscience is a biotech company focused on treating rare neurodegenerative diseases by targeting microglia, the brain's immune cells. Its market cap is a bet on a new approach to neuroscience, reflecting hopes for a breakthrough in this complex field.
Book value capitalization of the company, segment and market as a whole
VIGL - Book value capitalization of the company Vigil Neuroscience
Vigil Neuroscience is a biopharmaceutical company. Its book value represents its R&D capital. The chart below shows its financial resources for developing drugs for rare neurological diseases. This level is an indicator of its ability to fund its research programs.
VIGL - Share of the company's book capitalization Vigil Neuroscience within the market segment - Neuro
Vigil Neuroscience is a biotech company focused on treating rare neurological diseases. Its core capital is intellectual property, derived from scientific research. The share of physical assets will reflect its R&D-focused model.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Vigil, which develops drugs to treat rare neurodegenerative diseases, looks like a "lightweight." Its value lies in its scientific platform and patents, not in its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Vigil Neuroscience is a biotech company focused on treating rare neurological diseases. Its assets are not drugs, but rather a scientific platform and development pipeline. The company's balance sheet is invested in understanding and repairing microglia—the brain's immune cells that underpin the health of the entire nervous system.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Vigil Neuroscience
Vigil's balance sheet represents its cash flow. Its market capitalization represents its bet on its scientific approach to treating neurodegenerative diseases. The MvsBCap_Co chart shows how investors value the "hope" for a new brain drug compared to the company's actual cash balances.
Market to book capitalization ratio in a market segment - Neuro
Vigil Neuroscience develops drugs to treat rare neurodegenerative diseases by targeting microglia in the brain. Its value lies in its scientific approach. The graph shows a speculative estimate of its potential, which depends on the success of its drugs in clinical trials.
Market to book capitalization ratio for the market as a whole
Vigil Neuroscience specializes in drugs for the treatment of rare neurological diseases. The market values such companies not by their current assets, but by the likelihood of their research being successful. This metric demonstrates the enormous credibility of investors, reflected in a market valuation that significantly exceeds their book value.
Debts of the company, segment and market as a whole
VIGL - Company debts Vigil Neuroscience
Vigil Neuroscience, a company focused on rare neurodegenerative diseases, uses debt to fund its scientific mission. This chart shows how the company raises capital to conduct expensive clinical trials of its drug candidates. In this complex field of medicine, debt is the key to developing new treatments.
Market segment debts - Neuro
Vigil Neuroscience is a biotech company focused on treating rare neurodegenerative diseases by targeting microglia, the brain's immune cells. It's a groundbreaking approach. This chart shows how the clinical-stage company funds its expensive and risky research in this complex area of medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Vigil Neuroscience
Vigil Neuroscience is a company focused on developing drugs for rare neurological diseases. Its financial health depends entirely on research success. This chart shows how the company uses debt to finance its lengthy and expensive clinical trials, placing a heavy bet on scientific breakthroughs.
Market segment debt to market segment book capitalization - Neuro
Vigil Neuroscience is a biotech company focused on developing drugs to treat rare neurodegenerative diseases. Financing clinical trials requires capital. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Vigil Neuroscience (VIGL) is a biotech company focused on developing treatments for rare neurodegenerative diseases. Funding such cutting-edge research requires significant capital. This chart shows the overall market leverage, clearly demonstrating why VIGL is entirely dependent on investor capital during the R&D phase.
P/E of the company, segment and market as a whole
P/E - Vigil Neuroscience
This chart for Vigil Neuroscience, a company focused on treating rare neurodegenerative diseases, is a measure of hope. There is no price-to-earnings ratio. The company's valuation is based on the potential of its drugs targeting microglia—the brain's immune cells. Its performance depends entirely on success in clinical trials.
P/E of the market segment - Neuro
This chart illustrates the average P/E ratio for biotech companies working in neuroscience. For Vigil Neuroscience, it serves as a backdrop. It highlights the overall level of hope and disappointment in this complex field, providing context for assessing the risks associated with developing drugs to treat brain diseases.
P/E of the market as a whole
Vigil Neuroscience develops drugs to treat rare neurodegenerative diseases by targeting microglia, the brain's immune cells. This is a new approach in neuroscience. This chart shows the sentiment in the biotech sector. It helps understand how the market views this innovative scientific approach and the company's potential to treat diseases for which there is currently no effective therapy.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases. For a company in the research stage, this chart is a sign of hope. It reflects analysts' assessment of the scientific potential of its developments and the likelihood of future commercial success if the drugs are approved.
%20P%2FE%20Vigil%20Neuroscience&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Vigil-Neuroscience&v=1772636047172 "Chart of the company's future (projected) P/E Vigil Neuroscience")
Future (projected) P/E of the market segment - Neuro
Vigil Neuroscience specializes in developing drugs to treat rare neurodegenerative diseases by targeting microglia. This chart shows average expectations for the biotech sector. VIGL's position may indicate investor confidence in its scientific approach and the potential of its developments to create treatments for Alzheimer's and other diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772636047199 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Vigil Neuroscience develops drugs for the treatment of rare neurological diseases. The company's success is determined by scientific breakthroughs. Overall market sentiment, reflected in this chart, influences the availability of funding but not the likelihood of success of its clinical programs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636047221 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases by restoring normal microglia function. This graph shows cutting-edge brain research. The losses represent investments in R&D, while future profits depend on the success of their drugs in clinical trials.
Profit of companies in the market segment - Neuro
Vigil Neuroscience specializes in developing drugs to treat rare neurodegenerative diseases by targeting microglia, the brain's immune cells. Profitability in the neuroscience sector, as this chart demonstrates, lies in finding breakthroughs in one of the most complex areas of medicine. VIGL's success depends on its ability to demonstrate the effectiveness of its new approach.
Overall market profit
Vigil Neuroscience, a company focused on rare neurodegenerative diseases, operates in a field driven by science. The need for treatments for these diseases is independent of the economic situation, as this chart shows. However, for Vigil, as a young biotech company, the overall market situation is critical for raising capital for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Vigil Neuroscience
Vigil Neuroscience is focused on developing drugs for rare neurodegenerative diseases. This chart shows analyst forecasts, which are essentially estimates of the scientific potential of its developments. The forecast dynamics reflect the market's confidence in the success of its clinical programs and future commercial potential.
%20profit%20of%20the%20company%20Vigil%20Neuroscience&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Vigil-Neuroscience&v=1772636047290 "Graph of future (projected) profit of the company Vigil Neuroscience")
Future (predicted) profit of companies in the market segment - Neuro
Vigil Neuroscience is focused on developing treatments for rare neurodegenerative diseases by restoring the function of microglia, the brain's immune cells. This is a pioneering approach in neuroscience. This chart shows the revenue forecast for the neuroscience sector, reflecting the hopes for new therapeutic approaches to combat brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772636047371 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Vigil Neuroscience is a biotech company specializing in rare neurodegenerative diseases. Its value is determined by progress in clinical trials. Its overall profit outlook is affected indirectly by the investment climate. During downturns, investors tend to be risk-averse, making it difficult for early-stage companies to raise funds.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636047387 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on treating rare neurodegenerative diseases. Being in the clinical stage, it has no commercial revenue. Its price reflects investors' faith in its scientific approach and the potential of its drugs. The valuation is a bet on a future breakthrough in the treatment of brain diseases.
P/S market segment - Neuro
Vigil Neuroscience specializes in developing drugs to treat rare neurodegenerative diseases by targeting microglia, the brain's immune cells. The chart shows the average revenue valuation for the biotech company, providing insight into how highly investors value its innovative scientific approach to complex brain diseases.
P/S of the market as a whole
Vigil Neuroscience specializes in developing treatments for rare neurodegenerative diseases by targeting microglia, the brain's immune cells. This is a new approach in neuroscience. The graph of average market revenue estimates serves as a benchmark for understanding the enormous hopes for a scientific breakthrough that investors are factoring into the company's current price.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases. This chart visualizes investor expectations, valuing the company based on the significant future revenues its drug candidates could generate. This is a bet on the success of its scientific platform.
%20P%2FS%20Vigil%20Neuroscience&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Vigil-Neuroscience&v=1772636047632 "The graph of the company's future (projected) P/S Vigil Neuroscience")
Future (projected) P/S of the market segment - Neuro
Vigil Neuroscience specializes in developing drugs to treat rare neurodegenerative diseases by targeting microglia in the brain. This figure reflects the average future sales estimate for neuroscience companies. This provides an indication of how highly the market values Vigil's scientific approach and the commercial potential of its developments in the complex field of neuroscience.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772636047688 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Vigil Neuroscience is a biotech company focused on rare neurodegenerative diseases. Its value is driven by scientific breakthroughs. This revenue guidance chart is of little significance to the company. Investors are looking at the potential of its platform to treat diseases for which there are currently no effective solutions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636047745 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases. While in clinical trials, the company typically does not generate revenue from drug sales. Any revenue shown in this graph likely comes from affiliate payments that fund its scientific activities.
Sales of companies in the market segment - Neuro
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases. Their approach is based on restoring the function of microglia, key immune cells in the brain. This chart shows total revenue in the neuroscience sector, reflecting progress and investment in drug discovery for Alzheimer's, Parkinson's, and other diseases.
Overall market sales
Vigil Neuroscience is a biopharmaceutical company specializing in the treatment of rare neurodegenerative diseases. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases by targeting microglia. Its future depends on success in clinical trials. This chart reflects the market's assessment of the likelihood of commercial success for its therapeutic candidates.
%20sales%20of%20the%20company%20Vigil%20Neuroscience&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Vigil-Neuroscience&v=1772636047864 "Schedule of future (projected) sales of the company Vigil Neuroscience")
Future (projected) sales of companies in the market segment - Neuro
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases by restoring the function of microglia, the brain's immune cells. The chart shows forecasts for the neuroscience pharmaceutical sector. Vigil's success depends on breakthroughs in understanding and treating brain diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772636047872 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Vigil Neuroscience specializes in developing drugs to treat rare neurodegenerative diseases. For such a highly specialized company, overall capital inflows into biotechnology are important. This graph, reflecting investor confidence, impacts the availability of funding for long-term and risky microglia research, VIGL's focus.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636047932 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on developing drugs for rare neurodegenerative diseases. While in clinical trials, it is actively investing in research. This chart shows the company's financial trajectory, where current expenses form the foundation for future profits from successful drugs.
Market segment marginality - Neuro
Vigil Neuroscience is a biotech company focused on developing drugs for the treatment of rare neurodegenerative diseases. This chart shows the average revenue in the pharmaceutical industry. As a clinical-stage company, its future ability to exceed this figure depends entirely on the success of its developments and their commercialization.
Market marginality as a whole
Vigil Neuroscience is a biotech company focused on developing drugs to treat rare neurodegenerative diseases. It is in clinical trials, and its financial performance reflects its research expenditures. This total profitability chart highlights the gap between companies generating revenue and those investing in solving complex medical problems.
Employees in the company, segment and market as a whole
Number of employees in the company Vigil Neuroscience
Vigil Neuroscience is a biotechnology company focused on developing treatments for rare neurodegenerative diseases. Its work is based on cutting-edge science. This chart shows the size of its highly specialized team of neuroscientists and clinicians, who are the core of its drug discovery efforts.
Share of the company's employees Vigil Neuroscience within the market segment - Neuro
Vigil Neuroscience focuses on rare neurodegenerative diseases, developing therapies based on microglia—the brain's immune cells. This is a highly specialized field of science. This figure reflects the concentration of leading global neurobiologists and geneticists in this niche at Vigil, confirming its status as a center of cutting-edge brain research.
Number of employees in the market segment - Neuro
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases by targeting microglia. The growth of its scientific and clinical teams, reflected in the graph, is an indicator of progress. This increase in staff indicates the active advancement of candidate drugs through the development stages.
Number of employees in the market as a whole
Vigil Neuroscience focuses on rare neurodegenerative diseases using a genetic approach. This graph illustrates the biotech company's early development. A small but growing team of scientists specializing in microglia reflects progress in preclinical research and the approach to first human trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Vigil Neuroscience (VIGL)
Vigil Neuroscience is a biotech company focused on treating rare neurological diseases. In this sector, market capitalization depends almost entirely on the success of clinical trials and the potential of patented molecules. This metric reflects the high "innovation premium" the market attributes to the company's value per research scientist.
%20of%20the%20company%20Vigil%20Neuroscience%20(VIGL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Vigil-Neuroscience-VIGL&v=1772636048422 "Chart of market capitalization per employee (in thousands of dollars) of the company Vigil Neuroscience (VIGL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Vigil Neuroscience is focused on developing treatments for rare neurodegenerative diseases. Its market capitalization is driven by the prospects of clinical trials conducted by a small but highly qualified team. This chart shows how investors assess the company's scientific potential per employee.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772636048425 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Vigil Neuroscience specializes in developing drugs to treat rare neurodegenerative diseases. The chart illustrates the biotech's valuation in this complex field. The high market cap per employee demonstrates investors' belief that a small team of scientists can find the key to treating brain diseases where the need is enormous.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636048543 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Vigil Neuroscience (VIGL)
Vigil Neuroscience is a clinical-stage biotech company focused on treating rare neurodegenerative diseases (microglia). The company is not profitable. This chart shows the net loss (R&D costs) per scientist working on future breakthroughs in brain treatment.
%20Chart%20Vigil%20Neuroscience%20(VIGL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Vigil-Neuroscience-VIGL&v=1772636048629 "Company Profit Per Employee (in thousands of dollars) Chart Vigil Neuroscience (VIGL)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Vigil Neuroscience is a biotech company focused on developing treatments for rare neurodegenerative diseases by targeting microglia (brain immune cells). This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively Vigil is investing in its scientists to validate this new approach in neuroscience.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772636048715 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Vigil Neuroscience is a clinical-stage biotech focused on rare and common neurodegenerative diseases (e.g., ALSP). The company is in the R&D phase and is not commercially profitable. This chart shows the investment (loss) per scientist working on complex neuroscience problems.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636048737 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Vigil Neuroscience (VIGL)
Vigil Neuroscience develops drugs for the treatment of rare neurological diseases. For a research-stage biopharmaceutical company, this timeline reflects the onset of commercialization, for example, through the receipt of advance payments from partners, which confirms the potential of its scientific developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Vigil-Neuroscience-VIGL&v=1772636048768 "Sales chart per company employee Vigil Neuroscience (VIGL)")
Sales per employee in the market segment - Neuro
Vigil Neuroscience (VIGL) is a clinical-stage biotech focused on treating rare neurodegenerative diseases (microglia). The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Vigil Neuroscience is a biotech company focused on rare neurological diseases. This figure is expectedly low at the clinical development stage. The company is investing in its research staff without a commercial product. This timeline is important for tracking the future transition to commercialization and assessing the potential impact of their developments.
Short shares by company, segment and market as a whole
Shares shorted by company Vigil Neuroscience (VIGL)
Vigil Neuroscience (VIGL) is a biotech company focused on rare neurodegenerative diseases (ALSP). They use an approach based on microglia (brain immune cells). This chart shows bearish bets. This reflects the high risk: investors doubt their approach to treating these complex brain diseases will be successful.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Vigil-Neuroscience-VIGL&v=1772636048847 "Short Shares Chart for the Company Vigil Neuroscience (VIGL)")
Shares shorted by market segment - Neuro
Vigil Neuroscience is a biotech company focused on treating rare neurodegenerative diseases by targeting microglia (brain immune cells). This chart shows the total short interest across the entire neuroscience biotech segment. High values indicate significant investor skepticism about this challenging field, which has historically seen a high rate of clinical trial failures.
Shares shorted by the overall market
Vigil Neuroscience is a clinical-stage biotech focused on rare neurological diseases. This chart illustrates the overall market pessimism. When fear dominates, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like VIGL, preferring to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Vigil Neuroscience (VIGL)
Vigil Neuroscience (VIGL) is a biotech company focused on treating rare neurodegenerative diseases by targeting microglia (brain immune cells). This chart measures the rate of price change. It helps identify when investor enthusiasm (above 70) for trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Vigil-Neuroscience-VIGL&v=1772636048946 "RSI 14 indicator chart for the company's stock Vigil Neuroscience (VIGL)")
RSI 14 Market Segment - Neuro
Vigil Neuroscience is a "biotech" company, a "brain hunter." Their focus is on rare neurodegenerative diseases (ALSP) associated with microglia (brain immunity). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is VIGL's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Vigil Neuroscience (VIGL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VIGL (Vigil Neuroscience)
Vigil Neuroscience is a biotech company focused on treating rare neurodegenerative diseases by targeting microglia (brain immune cells). This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VIGL-Vigil-Neuroscience&v=1772636049074 "A chart showing analyst consensus forecasts for the expected stock price. VIGL (Vigil Neuroscience)")
The difference between the consensus estimate and the actual stock price VIGL (Vigil Neuroscience)
Vigil (VIGL) is a biotech company focused on microglia (the brain's immune cells). Their goal is to develop treatments for rare neurodegenerative diseases. This chart shows the difference between the market valuation and the consensus forecast. It highlights the potential (and risks) analysts see in this complex R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VIGL-Vigil-Neuroscience&v=1772636049101 "A chart showing the difference between the consensus forecast and the actual stock price. VIGL (Vigil Neuroscience)")
Analyst consensus forecast for stock prices by market segment - Neuro
Vigil Neuroscience is a biotech company focused on treating rare neurological diseases by targeting microglia (the brain's immune cells). This chart shows analysts' overall expectations for the entire neuroscience sector. It reflects whether experts believe a breakthrough in the treatment of neurodegenerative diseases is possible.
Analysts' consensus forecast for the overall market share price
Vigil Neuroscience (VIGL) is a brain "cleaner." It's a biotech company focused on microglia (the brain's immune cells). They're developing drugs for rare neurological diseases. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but high-risk, R&D projects in neuroscience.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Vigil Neuroscience
Vigil Neuroscience is a biotech company focused on treating rare neurodegenerative diseases by targeting microglia (brain immune cells). This approach is novel. This chart is a composite index reflecting market perception of their scientific platform, the risks of clinical trials in the complex field of neuroscience, and the availability of capital for development.
AKIMA Market Segment Index - Neuro
Vigil Neuroscience (VIGL) is a neurobiotech company focused on rare and common neurodegenerative diseases, focusing on microglia (the brain's immune cells). This chart compares their composite index to the neuropharma sector average.
The AKIM Index for the overall market
Vigil Neuroscience is a biotech company focusing on microglia (brain immune cells) for the treatment of neurodegenerative diseases (ALSP, Alzheimer's). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story compares to overall economic trends.
